Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies

Deborah L. Darrington, Julie Marie Vose, James R. Anderson, Philip Jay Bierman, Michael R. Bishop, Wing C. Chan, Mary E. Morris, Elizabeth Cecile Reed, Warren G Sanger, Stefano R. Tarantolo, Dennis D. Weisenburger, Margaret Anne Kessinger, James Olen Armitage

Research output: Contribution to journalArticle

307 Citations (Scopus)

Abstract

Purpose: To analyze the risk of developing myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) following autologous bone marrow transplantation (ABMT) or peripheral stem-cell transplantation (PSCT) and to determine the impact on failure-free survival (FFS). Patients and Methods: Patients underwent ABMT or PSCT for the treatment of Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) at the University of Nebraska Medical Center. For those patients who went on to develop MDS/AML, controls were selected and a case-control-within-a-cohort study undertaken. Results: Twelve patients developed MDS or AML a median of 44 months following ABMT/PSCT. The cumulative incidence (P = .42) and the conditional probability (P = .32) of MDS/AML were not statistically different between HD and NHL patients. Age greater than 40 years at the time of transplant (P = .05) and receipt of a total-body irradiation (TBI)-containing regimen (P = .06) were predictive for developing MDS/AML in patients with NHL. Conclusion: There is an increased risk of MDS/AML following ABMT/PSCT for lymphoid malignancies. NHL patients age ≥ 40 years at the time of transplant and who received TBI are at greatest risk.

Original languageEnglish (US)
Pages (from-to)2527-2534
Number of pages8
JournalJournal of Clinical Oncology
Volume12
Issue number12
StatePublished - Dec 1 1994

Fingerprint

Myelodysplastic Syndromes
Stem Cell Transplantation
Chemoradiotherapy
Acute Myeloid Leukemia
Peripheral Blood Stem Cell Transplantation
Autologous Transplantation
Bone Marrow Transplantation
Incidence
Non-Hodgkin's Lymphoma
Neoplasms
Whole-Body Irradiation
Hodgkin Disease
Transplants
Cohort Studies
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. / Darrington, Deborah L.; Vose, Julie Marie; Anderson, James R.; Bierman, Philip Jay; Bishop, Michael R.; Chan, Wing C.; Morris, Mary E.; Reed, Elizabeth Cecile; Sanger, Warren G; Tarantolo, Stefano R.; Weisenburger, Dennis D.; Kessinger, Margaret Anne; Armitage, James Olen.

In: Journal of Clinical Oncology, Vol. 12, No. 12, 01.12.1994, p. 2527-2534.

Research output: Contribution to journalArticle

Darrington, Deborah L. ; Vose, Julie Marie ; Anderson, James R. ; Bierman, Philip Jay ; Bishop, Michael R. ; Chan, Wing C. ; Morris, Mary E. ; Reed, Elizabeth Cecile ; Sanger, Warren G ; Tarantolo, Stefano R. ; Weisenburger, Dennis D. ; Kessinger, Margaret Anne ; Armitage, James Olen. / Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. In: Journal of Clinical Oncology. 1994 ; Vol. 12, No. 12. pp. 2527-2534.
@article{0ec1897a4a654cf9a06d0aa3cf6225e5,
title = "Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies",
abstract = "Purpose: To analyze the risk of developing myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) following autologous bone marrow transplantation (ABMT) or peripheral stem-cell transplantation (PSCT) and to determine the impact on failure-free survival (FFS). Patients and Methods: Patients underwent ABMT or PSCT for the treatment of Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) at the University of Nebraska Medical Center. For those patients who went on to develop MDS/AML, controls were selected and a case-control-within-a-cohort study undertaken. Results: Twelve patients developed MDS or AML a median of 44 months following ABMT/PSCT. The cumulative incidence (P = .42) and the conditional probability (P = .32) of MDS/AML were not statistically different between HD and NHL patients. Age greater than 40 years at the time of transplant (P = .05) and receipt of a total-body irradiation (TBI)-containing regimen (P = .06) were predictive for developing MDS/AML in patients with NHL. Conclusion: There is an increased risk of MDS/AML following ABMT/PSCT for lymphoid malignancies. NHL patients age ≥ 40 years at the time of transplant and who received TBI are at greatest risk.",
author = "Darrington, {Deborah L.} and Vose, {Julie Marie} and Anderson, {James R.} and Bierman, {Philip Jay} and Bishop, {Michael R.} and Chan, {Wing C.} and Morris, {Mary E.} and Reed, {Elizabeth Cecile} and Sanger, {Warren G} and Tarantolo, {Stefano R.} and Weisenburger, {Dennis D.} and Kessinger, {Margaret Anne} and Armitage, {James Olen}",
year = "1994",
month = "12",
day = "1",
language = "English (US)",
volume = "12",
pages = "2527--2534",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "12",

}

TY - JOUR

T1 - Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies

AU - Darrington, Deborah L.

AU - Vose, Julie Marie

AU - Anderson, James R.

AU - Bierman, Philip Jay

AU - Bishop, Michael R.

AU - Chan, Wing C.

AU - Morris, Mary E.

AU - Reed, Elizabeth Cecile

AU - Sanger, Warren G

AU - Tarantolo, Stefano R.

AU - Weisenburger, Dennis D.

AU - Kessinger, Margaret Anne

AU - Armitage, James Olen

PY - 1994/12/1

Y1 - 1994/12/1

N2 - Purpose: To analyze the risk of developing myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) following autologous bone marrow transplantation (ABMT) or peripheral stem-cell transplantation (PSCT) and to determine the impact on failure-free survival (FFS). Patients and Methods: Patients underwent ABMT or PSCT for the treatment of Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) at the University of Nebraska Medical Center. For those patients who went on to develop MDS/AML, controls were selected and a case-control-within-a-cohort study undertaken. Results: Twelve patients developed MDS or AML a median of 44 months following ABMT/PSCT. The cumulative incidence (P = .42) and the conditional probability (P = .32) of MDS/AML were not statistically different between HD and NHL patients. Age greater than 40 years at the time of transplant (P = .05) and receipt of a total-body irradiation (TBI)-containing regimen (P = .06) were predictive for developing MDS/AML in patients with NHL. Conclusion: There is an increased risk of MDS/AML following ABMT/PSCT for lymphoid malignancies. NHL patients age ≥ 40 years at the time of transplant and who received TBI are at greatest risk.

AB - Purpose: To analyze the risk of developing myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) following autologous bone marrow transplantation (ABMT) or peripheral stem-cell transplantation (PSCT) and to determine the impact on failure-free survival (FFS). Patients and Methods: Patients underwent ABMT or PSCT for the treatment of Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) at the University of Nebraska Medical Center. For those patients who went on to develop MDS/AML, controls were selected and a case-control-within-a-cohort study undertaken. Results: Twelve patients developed MDS or AML a median of 44 months following ABMT/PSCT. The cumulative incidence (P = .42) and the conditional probability (P = .32) of MDS/AML were not statistically different between HD and NHL patients. Age greater than 40 years at the time of transplant (P = .05) and receipt of a total-body irradiation (TBI)-containing regimen (P = .06) were predictive for developing MDS/AML in patients with NHL. Conclusion: There is an increased risk of MDS/AML following ABMT/PSCT for lymphoid malignancies. NHL patients age ≥ 40 years at the time of transplant and who received TBI are at greatest risk.

UR - http://www.scopus.com/inward/record.url?scp=0028110040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028110040&partnerID=8YFLogxK

M3 - Article

VL - 12

SP - 2527

EP - 2534

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 12

ER -